The FDA has proposed ending the use of a common ingredient found in many cold and allergy medicines — and some pharmacies ...
The company is establishing a North Carolina factory for cold medicine as postpandemic pharma demand has grown more ...
The FDA designated 166 products under its breakthrough devices program in its most recent financial year, reversing the ...
Belski is especially bullish on small- and mid-cap equities, calling them “the golden child of the next decade. I think that ...
Mizuho Securities analyst Uy Ear has maintained their neutral stance on RVNC stock, giving a Hold rating on November 11. Uy Ear’s rating ...
The Healthy on MSN1d
Multiple Over-the-Counter Decongestants May Be Pulled from the Market, Warns the FDAFor those sniffling, sneezing, stuffy head symptoms lurking right around the corner, see whether your preferred medicine will ...
Given these trial results, there remains uncertainty about emraclidine’s future prospects and AbbVie’s ability to present a competitive alternative in the schizophrenia treatment market, particularly ...
On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.
Donald Trump returning to the White House triggered new index records in the US, and major UK companies are likely to feel ...
Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks. Now they're getting on his nerves. The post These 2 former stock market darlings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback